🆕Just published🆕 #LCAM25 Editorial from #JTO Editor-in-Chief Alex Adjei: "Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal" 🔗 Read the full article here: www.jto.org/article/S155... @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #LCSM

Getting ready for #IASLC Asia Conference on Lung Cancer this week! Want to know more about #JTO #JTOCRR publications or Reviewer Workshop? Happy to connect in person. #ACLC25 @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #PeerReview #ScholarlyPublication

#WCLC25 It takes a village! Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social! @jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR

#WCLC25 Meet the Editors - Engaging Q&A session between meeting attendees and Editors-in-Chief, Dr Alex Adjei #JTO and Dr Emily Stone #JTOCRR. @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #scholarlypublishing

#JTO & #JTOCRR Editorial Reception This annual get-together at #WCLC25 lets editors, top reviewers, the editorial office teams and publisher reconnect in person in a meaningful way in the middle of a very busy conference. @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social

#WCLC25 Reviewer Workshop - Here are the next generation of reviewers! It’s heartwarming to know many attendees came here just for this workshop. A few dedicated participants attended online despite unforeseen circumstances. I’m grateful for all of you, faculty and participants. @iaslc.bsky.social

#WCLC25 Happening now: IASLC Reviewer Workshop. Alex Adjei - “Top 10 of the do’s and dont’s as a reviewer” @iaslc.bsky.social @jtoonline.bsky.social #JTO #JTOCFR #peerreview

#WCLC25 Our #JTO editors got many talents! @drtomjohn.bsky.social @drsanjaypopat.bsky.social @jtoonline.bsky.social @iaslc.bsky.social

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

#WCLC25 WS04: Joint IASLC-CSCO-CAALC session happening now in Room 06. Case presentations and discussions with the panelists with global perspectives. @iaslc.bsky.social

🆕Special article by Lippman and colleagues in #JTO 📰Press release by UCSD: today.ucsd.edu/story/cancer... @ucsdcancer.bsky.social @iaslc.bsky.social @sciencedirect.bsky.social @elsevierhms.bsky.social @jtoonline.bsky.social #LCSM

Early weight gain as a risk factor for increased maximum weight gain among NSCLC patients on lorlatinib & other ALK tyrosine kinase inhibitors - JTO Clinical and Research Reports. #LCSM #LungCancer www.jtocrr.org/article/S266...

✍️June #JTO Editor’s pick 3 of 4: Deuterated Osimertinib 🆓 access: www.jto.org/article/S155... 📎 Also see Deuterated Lorlatinib: www.jto.org/article/S155... 📎 Accompanying editorial: www.jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #LCSM

🆕 #JTO Review Article from the #IASLC Basic and Translational Science Committee 🆓 access to full texts 🔗 jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #lungcancer

🆕 #JTO Review Article from IASLC Advanced Radiation Technology subcommittee 🔗 www.jto.org/article/S155... #OpenAccess @iaslc.bsky.social @jtoonline.bsky.social @elsevierconnect.bsky.social

Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!

Full support to Alex Adjei for President-Elect in 2025 #IASLC Board of Directors Election! I have worked with him for 10+ years, inspired by his strong leadership, vision, advocacy, and dedication to patient care, research and publication, and mentoring the next generations. @iaslc.bsky.social

@jtoonline.bsky.social @iaslc.bsky.social #JTO #sclc

Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study www.jto.org/article/S155... The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation.

Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) www.jto.org/article/S155... These findings suggest that gut microbiota profiling could help optimize treatment strategies for NSCLC.

⏰NOW OUT‼️ #ELCC25 🔥MARIPOSA🦋: Amivantamab plus lazertinib vs osimertinib in 1L EGFRm advanced NSCLC: Final OS 🎙️Prof. James Yang 🎯OS HR 0.75 (95%CI: 0.61-0.92) 🎯Seems like extending the OS for 1️⃣2️⃣ months ✅NCT04487080 #LCSM #EGFR @oncoalert.bsky.social @myesmo.bsky.social @iaslc.bsky.social

MARIPOSA final OS analysis ❇️ Significant HR 0.75 ❇️ 9% 3yr benefit ❇️ Projected mOS 4 years ❇️ Longer control of CNS disease ❗️At the cost of toxicity ❗️No data on duration of toxicity ❗️PROM and QoL data important More effective than Osimertinib Most suitable for higher risk pts #ELCC25

Congratulations to Keith Kerr, a long-time IASLC member, for receiving the 2025 Heine H Hansen Award at #ELCC2025 👏🏽👏🏽

In January 2025, we joined Taiwan Association for the Study of Lung Cancer (TASLC) in running a reviewer workshop in Taipei. 20 selected participants from Taiwan, Malaysia, Thailand, South Korea & Japan attended the workshop. Thanks TASLC for organizing and support! @jtoonline.bsky.social

Don’t miss out on this training opportunity! #IASLC Reviewer Workshop applications close on April 1. 🔗 www.iaslc.org/reviewer-wor... @jtoonline.bsky.social @iaslc.bsky.social #JTO #JTOCRR #reviewer

🌟 @iaslc.bsky.social @jtoonline.bsky.social 🔥Recipients of TOP5️⃣REVIEWERS 1️⃣Dr. Paolo Bironzo 2️⃣Dr. Nicolas Girard 3️⃣Dr. William Evans 4️⃣ @hhorinouchi.bsky.social 5️⃣Dr. Voon Pei Jye 🎉Congratulations🎊 #LCSM @oncoalert.bsky.social

🔥 @jtoonline.bsky.social 🆙 ✅JCOG2007 (NIPPON): Gut Microbiota in Advanced NSCLC Receiving Chemo-ICI 🎯Differences in microbial diversity and specific bacterial genera were associated with prognosis and serious AEs 👥 Dr. Taiki Hakozaki #LCSM @oncoalert.bsky.social jto.org/article/S155...

🔥 @iaslc.bsky.social @jtoonline.bsky.social 🆙 🥰TOP10 reviewers for 2024 Dr. Jordi Remon Dr. Dipesh Uprety Dr. Molly Siu Ching Li Dr. Kuan-Yu Chen Dr. Junko Tanizaki Dr. Tomer Meirson Dr. Stephanie Saw @hhorinouchi.bsky.social Dr. Misako Nagasaka Dr. Jean-Louis Pujol #LCSM jto.org/article/S155...

🔥 @jtoonline.bsky.social 🆙 ✅CROWN👑5y: First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC 🎯HR 0.22 (95%CI: 0.13‒0.37), 5-year PFS was 63% (95% CI: 49–74) by lorlatinib 👥 Prof. Yi-long Wu #LCSM @oncoalert.bsky.social jto.org/article/S155...

Members from Europe, Africa and the Middle East - don’t miss this opportunity to learn how to review manuscripts. ⏰ Deadline to apply: April 1 IASLC Reviewer Workshop: www.iaslc.org/reviewer-wor... @jtoonline.bsky.social @iaslc.bsky.social #reviewer #JTO #JTOCRR

On this International Women's Day, we celebrate the remarkable women in thoracic oncology who continue to break barriers, lead groundbreaking research, and inspire future generations. Their contributions are vital to shaping the future of lung cancer treatment and advancing equity in medicine.

Greatly appreciate the top 5 AND all the reviewers who reviewed for JTO! You can see the full list here: www.jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social #reviewer

🏆 Congrats to the Top 5 Reviewers for JTO in 2024! 🏆 Your dedication ensures the highest quality research. Thank you to Jordi Remon Masip, Dipesh Uprety, Molly Siu Ching Li, Kuan-Yu Chen, and Junko Tanizaki for your dedication! 👏 🔹 Apply for the 2025 Reviewer Workshop: bit.ly/ReviewerWS

2025 CTONG Young mtg in Guangzhou, China - Wonderful opportunity to engage w/ early-career researchers in thoracic oncology from the region in productive discussions. I look fwd to more connections & future collaboration. Honorary Chairs: 吴一龙,周清,钟文昭 Chairs: 张嘉涛,吴芳 @jtoonline.bsky.social

🔥 Top 🔟 Most Cited 2024 Articles in JTO 🔥 🧵 @jtoonline.bsky.social @iaslc.bsky.social @elsevierconnect.bsky.social #LCSM

#WorldCancerDay - Thanks #Elsevier for including Journal of Thoracic Oncology articles in this special collection ➡️ Read the #JTO collection here: www.sciencedirect.com/journal/jour... @iaslc.bsky.social #lungcancer

We still have a long way to go to ensure that ALL patients benefit from recent scientific advances in #lungcancer. This study found that overall survival increased by 71% in patients with private insurance compared to only 24% in the uninsured in the US. #LCSM www.jtocrr.org/article/S266...

🔥 @jtoonline.bsky.social 🆙 ✅Lung cancer screening program quality indicators – review & recommendations 🎯An International Association for the Study of Lung Cancer Delphi process study 👥Dr. Martin C. Tammemägi #LCSM @oncoalert.bsky.social www.jto.org/article/S155...

Members from Europe, Africa and the Middle East ➡️ Interested in learning how to review manuscripts? Apply now ➡️ www.iaslc.org/reviewer-wor... #JTO #JTOCRR #peerreview @jtoonline.bsky.social @iaslc.bsky.social #WCLC25

A story of controversy: During my time as Reviews Editor at the Journal of Thoracic Oncology, Alex Adjei, the editor -in-chief accepted my pitch to have these pro/cons. Inspired by some of the sport seen in fun conference debates. www.sciencedirect.com/science/arti...

🆕 A Perspective article on the MARS2 trial by Lim et al. is published online in #JTO ➡️ www.jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social @elsevierconnect.bsky.social #mesothelioma #LCSM @oncoalert.bsky.social @oncodaily.bsky.social

5 papers about Lung Cancer suggested by Stephen Liu @stephenvliu.bsky.social oncodaily.com/insight/lung... #Cancer #CancerResearch #CheckMate204 #CHRYSALIS2 #EGFR+NSCLC #LungCancer #NSCLC #OncoDaily #Oncology #OPEN/TORG2040 #SCLC #TROPiCS-03

💡Interested in learning how to review a manuscript? Join IASLC Reviewer Workshop ➡️ Open to members in Europe 📅 Applications open Jan 24 🌐 More details www.iaslc.org/reviewer-wor... @iaslc.bsky.social @jtoonline.bsky.social #reviewer #WCLC25

NORA - recently accepted at #JTO www.jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social @elsevierconnect.bsky.social #LCSM #OpenAccess

🆕Just accepted at #JTO www.jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social @elsevierconnect.bsky.social #LCSM

Attention Lung Cancer patients! Please participate in this research survey. It only takes about 10 minutes. www.surveymonkey.com/r/37P79WB @devikadasmd.bsky.social @ishwaria.bsky.social #lcsm

@iaslc.bsky.social @jtoonline.bsky.social #LCSM

This post brought to you by Lung Cancer research funding. Denise Marshall (with daughter Corrine) died a few days ago 7 YEARS after she was on hospice with LC. Those years are a direct result of LC research. Can you imagine what could happen with fair & equitable research funding? #lcsm #oncsky

Thanks @oncoalert.bsky.social for the shoutout! #JTO Brief Report: www.jto.org/article/S155... @jtoonline.bsky.social #LCSM @iaslc.bsky.social